Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.42 |
| ▸ | CCR2 | P41597 | 4/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | CCR3 | P51677 | 2/20 | 0.41 |
| ▸ | ACLY | P53396 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440516 | 1.00 | HKDC1 (0.49) | HKDC1KEAP1CCR2CCR1NFE2L2 | |
| SCHEMBL1775450 | 1.00 | HKDC1 (0.49) | HKDC1KEAP1CCR2CCR1NFE2L2 | |
| SCHEMBL1776784 | 0.94 | HKDC1 (0.51) | HKDC1KEAP1CCR2CCR1NFE2L2 | |
| SCHEMBL1774545 | 0.89 | KEAP1 (0.56) | HKDC1KEAP1NFE2L2 | |
| SCHEMBL1775565 | 0.87 | STS (0.53) | HKDC1 | |
| SCHEMBL1777387 | 0.87 | STS (0.53) | HKDC1 | |
| SCHEMBL1775295 | 0.84 | CCR2 (0.44) | CCR2MEN1POLBKMT2A | |
| SCHEMBL1774949 | 0.83 | KEAP1 (0.58) | HKDC1KEAP1NFE2L2 | |
| SCHEMBL1775632 | 0.78 | CCR2 (0.45) | CCR2MEN1POLBKMT2A | |
| SCHEMBL1775566 | 0.77 | HKDC1 (0.45) | HKDC1KEAP1CCR2CCR1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | disclosed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | HKDC1 3313/4885KEAP1 2442/4885CCR2 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.